Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".
Publication
, Journal Article
Affronti, ML; Herndon, JE; Patel, MP
Published in: Support Care Cancer
December 2020
Duke Scholars
Published In
Support Care Cancer
DOI
EISSN
1433-7339
Publication Date
December 2020
Volume
28
Issue
12
Start / End Page
5591 / 5592
Location
Germany
Related Subject Headings
- Vomiting
- Temozolomide
- Ondansetron
- Oncology & Carcinogenesis
- Nausea
- Humans
- Glioma
- Aprepitant
- Antineoplastic Agents
- 52 Psychology
Citation
APA
Chicago
ICMJE
MLA
NLM
Affronti, M. L., Herndon, J. E., & Patel, M. P. (2020). Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide". Support Care Cancer, 28(12), 5591–5592. https://doi.org/10.1007/s00520-020-05726-0
Affronti, Mary Lou, James E. Herndon, and Mallika P. Patel. “Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".” Support Care Cancer 28, no. 12 (December 2020): 5591–92. https://doi.org/10.1007/s00520-020-05726-0.
Affronti ML, Herndon JE, Patel MP. Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide". Support Care Cancer. 2020 Dec;28(12):5591–2.
Affronti, Mary Lou, et al. “Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".” Support Care Cancer, vol. 28, no. 12, Dec. 2020, pp. 5591–92. Pubmed, doi:10.1007/s00520-020-05726-0.
Affronti ML, Herndon JE, Patel MP. Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide". Support Care Cancer. 2020 Dec;28(12):5591–5592.
Published In
Support Care Cancer
DOI
EISSN
1433-7339
Publication Date
December 2020
Volume
28
Issue
12
Start / End Page
5591 / 5592
Location
Germany
Related Subject Headings
- Vomiting
- Temozolomide
- Ondansetron
- Oncology & Carcinogenesis
- Nausea
- Humans
- Glioma
- Aprepitant
- Antineoplastic Agents
- 52 Psychology